JNJ-56021927
JNJ-56021927 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
100.0%
3 of 3 finished
0.0%
0 ended early
1
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927
Clinical Trials (4)
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4